Acrivon Therapeutics
MA - WatertownBiotechnology
Focus: Acrivon Therapeutics is an oncology-focused biotech company developing checkpoint inhibitor-based cancer immunotherapies. The company is early-stage with a small clinical pipeline in Phase 1–2.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Acrivon Therapeutics?
AI assessmentSuitable for early-career or mission-driven professionals willing to accept high execution risk for potential upside in a focused immunotherapy platform.
Why Work Here
- Ground-floor opportunity at a focused oncology immunotherapy company with active clinical programs in high-value indications (head and neck cancer, solid tumors)
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACR-2316
Advanced Solid TumorsClinical Trials (1)
NCT06667141Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Phase 1Help build intelligence for Acrivon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.